Dr. Madduri on the Potential Impact of CAR T-Cell Therapy in Multiple Myeloma

Video

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the potential impact of CAR T-cell therapy in multiple myeloma.

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the potential impact of CAR T-cell therapy in multiple myeloma.

There are several CAR T-cell products that are being explored in myeloma, most of which target BCMA. It’ll be important to wait for the data to come out of these trials because each product would preclude exposure to another in practice, explains Madduri. For example, if a BCMA bispecific monoclonal antibody is given, a bispecific CAR T-cell therapy cannot be given and vice versa. It will also be interesting to see what patients are chosen to participate in these studies, she adds. There is also a lot of ongoing research exploring CAR T-cell resistance, persistence, and relapse.

Every year, more therapies are being approved in myeloma. Most recently, the FDA approved selinexor (Xpovio) for the treatment of penta-refractory patients. Now, the phase I CRB-401 trial (NCT02658929) of bb2121 has completed enrollment. A biologics license application for the agent may be submitted to the FDA early next year, says Madduri.

Moreover, there are going to be commercially available CAR T-cell therapies, which is going to change the treatment paradigm very quickly. However, it remains to be seen whether patients who progress on BCMA bispecific monoclonal antibodies will derive any benefit from CAR T-cell therapy in the real-world setting.

Related Videos
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
© 2024 MJH Life Sciences

All rights reserved.